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Abstract 
Osteoarthritis (OA) is a debilitating chronic condition widely prevalent in ageing populations. Whilst 
pathology includes cartilage erosion and joint re-modelling, patients experience great pain.  Despite 
numerous studies, the details are frequently inseparable from other types of chronic pain and causes 
are unknown. Cartilage lacks afferent innervation in most circumstances, but other joint tissues con-
tain nociceptive neurones.  In addition to physical joint damage there is a strong element of joint 
inflammation. Genetic studies have identified several associations between ion channels and OA 
pain including NaV1.7, P2X7 and TRPV1, however, several other channels are also implicated.  Many 
ion channels involved with OA pain are common to those seen in inflammatory pain. This review 
considers causes of OA pain and discusses three possible pain-reducing strategies involving ion chan-
nel modulation: Chondroprotection, innate afferent nerve inhibition and inhibition of inflammatory 
hyperalgesia.  A number of ion channels could be future targets for OA pain analgesia. 
 
 
Introduction 
Osteoarthritis (OA) is one of the most common causes of disability in the UK and the Royal College of 
Physicians estimates that 8.5m older people are affected in the UK alone[1]. When describing their 
symptoms at a relatively early stage of diagnosis, rheumatoid arthritis patients will often state that 
they have a debilitating stiffness, but OA patients will routinely present chronic pain.  Pain arising 
from affected joints may occur spontaneously without direct activation from an external stimulus.  
One symptom of OA is mechanical hyperalgesia[2]; although pain is often experienced at rest too[3].  
Other hallmarks of OA include formation of bone spurs (osteophytes), erosion of cartilage and 
inflammation of joint tissues.  Ion channels are potential targets for OA analgesia since they are 
critical to formation of cartilage and inflammatory pain.  Earlier this year the UK National Institute 
for Health and Care Excellence draft guidance on OA treatment cautioned against excessive use of a 
wide range of analgesics (including paracetamol/acetaminophen) and so the search for novel OA 
analgesics has become a research priority area.  This review considers sources of OA pain including 
joint nociceptor ion channels and nociceptive primary afferent neurones.  We will not discuss the 
complex topic of spinal and supra-spinal pain processing in detail, but these were reviewed recently 
by Zhang et al[4].  We explore the potential of ion channel modulating drugs and biologics to reduce 
pain and improve the quality of life – if not reduce disease progression.  
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Joint nociception.   
Many joint afferent neurons are peptidergic (calcitonin gene related peptide (CGRP)/substance P 
(SP) expressing) C and Aδ sensory afferents[5-7], 
i.e. typical nociceptive nerves.  Most parts of the 
joint receive nociceptive innervation; ligaments, 
meniscus, subchondral bone and synovium 
(Figure 1).  Although cartilage is usually aneural, 
under certain circumstances, it does contain no-
ciceptive neurones[8-9].  These could be a 
transient developmental stage before the tertiary 
structure of the joint is fully formed or the result 
of joint damage and remodelling, but clearly such 
neurones could initiate considerable pain.  Aδ- 
and C-fibres innervating any or all joint tissues 
are likely to be activated during OA onset – 
whether this results from direct mechanical 
(bone-on-bone) activation, abnormal joint 
loading (e.g., excessive ligament stretch) or in-
flammation (e.g., in the synovium).  It was once 
believed that there was no correlation between 
MRI analysis of joint degeneration and patient 
reported pain, but as MRI analysis increases in 
sophistication the discourse is progressively de-
creasing[10].  Recent studies show clear 
correlations between the presence of cartilage-
denuded zones of subchondral bone in knee joints 
and pain severity[11].   
Joint tissue damage leads to local inflammation and sensitisation of neurones[12], but may also 
promote the formation of neuroma or ingrowth of nociceptive neurones, leaving scope for the 
generation of neuropathic pain.  Currently, one of the greatest barriers in OA research is to establish 
the initial mechanism of pain generation.  Afferent nociceptive neurones synapse first in the spinal 
cord dorsal horn, then ascend to the reticular formation or thalamus before finally reaching the 
somatosensory cortex (Figure 1).  Potentially any step along this route, from chondrocyte to brain, 
could contribute to OA pain and is an attractive target for novel analgesics.  
 
Figure 1: Innervation of a typical articular joint. Most 
tissues of the joint receive afferent innervations includ-
ing C and Aδ neurones.  These project to the dorsal 
Rexed laminae layers of the spinal cord, especially the 
substantia gelatinosa via dorsal root ganglia (DRG).  In 
man, these afferent neurones typically synapse, then 
decussate and ascend contralaterally in the spinotha-
lamic or spinoreticular tract.  In non-primates the role of 
the spinothalamic tract is less clear and a greater pro-
portion of nociceptive signal ascends via bilateral dorsal 
columns or spinoreticular tract[113].  Non primates also 
frequently have a considerable spinocervicular 
component of ascending neurones; in the cat and dog 
these are particularly important for sensory 
innervations of the nucleus proprius[114] along the 
length of the spinal cord.  Conscious perception of pain 
4 
Ion channels in cartilage:  “Chondroprotection”. 
Since there is now an established link between cartilage erosion and OA pain[11], a clear strategy for 
pain reduction would be to slow cartilage erosion or stimulate cartilage production.  OA is associated 
with hypocellularity[13]; therefore it seems likely that a loss of chondrocytes contributes to disease 
progression[13]. Potentially chondroprotection will limit cartilage loss and thus reduce OA pain.  
Such chondroprotective drugs which could do this would be classed as disease modifying OA drugs
[14].  The mechanism and sequence of events leading to the loss of cartilage are unknown; it is 
thought that it involves a loss of balance between extracellular matrix (ECM) synthesis, maintenance 
and destruction.  This involves a range of matrix proteins and enzymes, many of which have been 
reviewed elsewhere[12, 15-17].  Gene wide association studies (GWAS) of OA demonstrate 
associations with a number of loci[18].  These genes mostly encode factors involved with 
chondrogenesis, endochondral ossification or apoptosis, rather than structural components of the 
ECM.  Some of the genes identified are directly associated with channel activity including: 
TMEM30A; this is believed to encode a phospholipid channel or transporter-associated transmem-
brane protein[19], PTHLH/PTHrP; encodes parathyroid hormone-like hormone/hormone-related 
peptide and has been shown to inhibit voltage-gated calcium channel (VGCC) activity in neurones
[20], RUNX2; a transcription factor which regulates chondrocyte pannexin channels[21] and, 
importantly, SMAD3; which inhibits transcription of an acid sensing ion channel (ASIC3) in 
chondrocyte-related nucleus pulposus (intervertebral disc) cells[22].  ASIC3 is strongly implicated in 
manifestation of OA pain (see below).  Only five genes have been directly associated with OA pain
[23]. Of these three were ion channels:  SCN9A; encoding the voltage-gated sodium channel NaV1.7. 
P2X7; a purinergic ligand-gated ion channel and TRPV1; the transient receptor potential channel va-
nilloid subtype 1.  GWAS do not indicate where the associated gene fits into the progression of dis-
ease or the pain, but most of these channel families have been implicated in joint pharmacological 
experiments (discussed below). Alternatively, for a number of individuals, sudden joint impact may 
initiate a sequence of events leading to cell death, hypocellularity and subsequent cartilage erosion
[24].  It has also been suggested that changes in osmotic environment (due to ageing or impact) 
could promote cell shrinkage and apoptosis[25].   Several ion channels are likely to be involved with 
this process including chloride[26] and potassium channels[27]; Kumagai et al[26] found the swelling
-activated chloride ion channel to be central to this process.  Inhibition of this channel could provide 
chondroprotection and would, ultimately, reduce pain.  Pharmacological targeting of chloride 
channels is difficult because there are few sufficiently specific inhibitors and the molecular identity 
of the chondrocyte chloride channels is unknown.  Recent bioinformatic analysis of the OA chondro-
cyte transcriptome identified differential expression of the TMEM16A chloride channels in OA chon-
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drocytes[28].  Further ion channels could also be functionally changed in chondrocytes from OA 
subjects. For example, the ATP sensitive potassium channel (KATP) is expressed in chondrocytes[29] 
and appears functionally impaired in OA[30], although not apparently changed at the transcript level
[28].  There are therefore several ion channels of chondrocytes which could be chondroprotectant 
targets, or indeed targets to halt the production of inflammatory mediators.  These have been 
further discussed elsewhere[25, 28, 31-33]. 
 
Ion channels in innate primary nociceptive afferents. 
Since the joint contains a number of nociceptive afferent neurones, it is likely that much of the pain 
of OA originates in the joint itself.  One possible means of establishing this would be to inject local 
anaesthetics (LA).  Typically, LAs work by inhibition of voltage-gated sodium channels, although lido-
caine can also inhibit TRPA1 channels[34], which are important mediators of chronic pain (see be-
low).  Usage of LAs has the potential limitation that the synovium itself is a rather acidic tissue, and 
will be further acidified during inflammation.  LAs are typically less effective in low pH[35] tissues 
since they are bases and only the charged form of the drug is inhibitory.  Despite this limitation they 
can be effective in some patient cohorts with knee[36] and hip pain[37].  Nerve block itself, 
however, is frequently ineffective[38].  Current LAs are generally unsuitable for treatment of chronic 
joint pain, as the half-life of pain relief is too short and high doses of some LAs are chondrotoxic[39].  
Until effective disease-modifying drugs are available, an alternative logical target is the primary 
afferent neurone.  Cartilage erosion or abnormal joint loading could activate these neurones and 
create pain even in the absence of neuroplasticity, but broad evidence suggests that these neurones 
are hyperactive in a range of OA models[40]. Nociceptors are typically activated by chemical/
mechanical stimuli and/or noxious temperatures.  Numerous studies have investigated which ion 
channels are present in joint primary afferents. VGCC, TRPV1, TRPV2 and P2X3 receptor-
immunoreactive innervation have all been observed in rat joints[41-42]. Furthermore, TRPV1 has 
also been identified in both healthy and OA rat knee[43-44].  Mechanogated (stretch-activated) 
channels, sensitive to gadolinium and amiloride have also been found in a range of joint tissues 
including cartilage[33, 45] and small afferent C and Aδ neurones[46]. The identity of the stretch-
activated ion channel present in joint afferent neurones is unknown, but one possible candidate is 
TRPV4, since it is present in afferents[47] and sensitive to mechanical stimulation[48].  Such stretch-
activated channels have been identified in joints and are inhibited by hylan, which may be poten-
tially useful therapeutically[49].  Besides targeting the ion channels themselves, block of conduction 
of nociceptive primary afferents is also a potential route to analgesia in OA, to which end the Nav1.8 
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inhibitor (A-803467) has shown promising results reducing joint nociception to mechanical stimuli
[50].  
It is important to highlight a limitation in the understanding of OA pain; it is not known if 
there are any specific differences between nociceptive afferents innervating the joints and those 
innervating other peripheral tissues.  This means that drugs for the treatment of joint pain will have 
a parallel affect on other nociceptive afferents within the body, or will have to be applied to just the 
affected area.  Evidence suggests that topically applied anti-inflammatory drugs (e.g., diclofenac) can 
reach affected human synovial joints[51], however there is little data on off-target bioavailability.  
Off-target nociception is not ideal, but may not be highly problematic.  It is critical that inhibitors of 
nociception do not inhibit other somatosensory afferents such as those conducting proprioception 
or kinaesthesia, since this could cause joint destabilization, accelerating the progression of OA, (see, 
for example, [52]).  Since pain is itself a protective signal to animals, it is important to consider that, 
used in isolation, effective analgesia itself could result in patients overusing joints which still have 
the same structural damage. 
 
Inflammatory activation of 
ion channels in OA pain 
OA can, in part, be distin-
guished from rheumatoid 
arthritis by the lack of sys-
temic markers for inflam-
mation; however, consider-
able evidence also links OA 
with joint inflammation. It 
has been suggested that 
OA may frequently result 
from biomechanical damage 
leading to chondrocyte driven inflammation and remodelling[12].  In addition to their role in carti-
lage production, chondrocytes have a direct role in inflammatory pain too, producing mediators 
which can both sensitise and activate neurones (Table I)[12, 53]. Pelletier et al[54]showed that chon-
drocytes obtained from OA patients actively produce nitric oxide (NO), prostaglandins, interleukin-1 
beta (IL-1β), tumor necrosis factor alpha (TNF-α), IL-6, and IL-8.  Inflammatory mediators are also 
produced by the synovial membrane and diffuse into cartilage. Here they manifest structural altera-
Table I. Inflammatory mediators produced by chondrocytes. 
Inflammatory mediators produced by chondrocytes, which have also been shown 
to modulate neuronal activity. Table modified from [12] with permission.  Other 
references: NGF production in chondrocytes [115]. *Shown in joint tissue, but not 
shown to be produced by chondrocytes [75-76]. PGE2, prostaglandin E2 
 
Direct sensitizers Indirect sensitizers Stimulators 
Prostaglandin E2  Bradykinin*  ATP 
Prostaglandin F2 Noradrenalin  Bradykinin* 
Prostaglandin I2  Leukotriene B4  Histamine 
ATP  Interleukin-1  Potassium 
Bradykinin*  Interleukin-8  Proton 
Proton NGF-OP  PGE2 
Tumor necrosis factor Tumor necrosis factor   
Interleukin-6 Nitric oxide  
Substance P   
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tions associated with OA disease progression[53].  Inflammatory mediators affect a range of ion 
channels, although it is unclear which channels and mediators are critical in OA pain. TNFα is one 
very strong candidate since anti-TNFα monoclonal antibody (adalimumab) produces a prolonged 
reduction of pain symptoms in an animal model[55].  TNFα has also been shown to directly modu-
late both VGCC and NaV currents in DRG neurons, causing a decrease in VGCC conductance and an 
increase in NaV[56]. Since gain of function of NaV1.8 results in painful neuropathy[57], restricting the 
effects of TNFα could potentially reduce this NaV-induced hyperalgesia.  Several ion channels have 
been directly linked to these processes in joint inflammation and OA and are discussed below. 
Sodium channels 
The sodium voltage-gated family includes 9 sub-members NaV1.1 to NaV1.9; these are the principal 
channels involved with the upstroke of action potentials in nearly all mammalian neurones.  The tet-
rodotoxin resistant NaV1.8 is of particular relevance to analgesia, because it is most predominant in 
smaller C-fibre nociceptors.  Epigenetic silencing of NaV1.8 leads to hypoalgesia[58] and over activity 
would be expected to decrease pain thresholds[57].  A decrease in pain thresholds appears to be 
one of the effects of pro-inflammatory prostaglandins (whose receptors are heavily expressed in 
DRG and peripheral nerve fibres), which have been found in a number of studies to be involved in 
OA disease progression as well as being key mediators of pain. There are intriguing differences in the 
actions of the key prostaglandin E2 (PGE2) receptors in OA[59].  Activation of the prostaglandin EP2 
and EP4 neuronal cell receptors stimulates pain and causes elevated levels of cyclic adenosine mo-
nophosphate (cAMP), whereas activation of EP3 is analgesic and causes decreases in cAMP[59].  
Natura et al[59] showed that cAMP in primary afferents increases activity of NaV1.8/9.  Activation of 
the prostaglandin EP2 and EP4 neuronal cell receptors stimulates pain and causes elevated levels of 
cAMP, whereas activation of EP3 is analgesic and causes decreases in cAMP[59].  In addition to its 
beneficial effects for mechanically-induced pain, blocking the voltage-gated NaV1.8 using antisense 
oligonucleotides has been shown to eliminate the generation of spontaneous activity in a CFA-
induced model of chronic inflammatory pain[60].  As well as NaV1.8 being of high importance in no-
ciceptive transmission, Aδ-neurones are also central to this and therefore it would seem that NaV1.6 
is particularly important. Knock-down of NaV1.6 reduced pain in a spinal inflammatory rat pain 
model, but left C-fibres largely unaffected[61]. Interestingly NaV1.7, identified in the association 
studies[23] and upregulated in a CFA model of chronic inflammatory pain[62], has not been impli-
cated in functional studies of afferent neurones, although characterisation of this channel is chal-
lenging due to a lack of selective pharmacological agents. 
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Acid sensing channels 
While there are a number of pH sensitive ion channels, ASICs are the most strongly associated with 
OA.  ASIC are a family of ion channels which preferentially conduct sodium and potassium ions.  The 
inflammation of synovial tissue during progression of OA results in acidification which could result in 
change of activity of ion channels.  Increased activity of acid sensitive ASIC or TRP channels could 
predispose neurones to excessive firing (and ultimately pain).  ASIC are found in several joint tissues 
including chondrocytes themselves[63], where their block can reduce articular cartilage erosion in 
adjuvant-induced OA[64].  ASIC3 are found in joint primary afferents innervating synovial tissue and 
are increased in expression in MIA-induced OA[65-66].  Selective block of this channel by intra-
articular administration of a peptide inhibitor (APETx2) reduced pain and inhibited disease progres-
sion[65].  A novel ASIC blocker, A-317567, has been reported to cause a reduction in hyperalgesia in 
models of inflammatory and post-operative pain[67]. However, there have been no clinical OA stud-
ies to date which describe the therapeutic benefit of ASIC inhibitors.  It should be noted that a role 
for ASIC1a in chronic OA pain would be rather intriguing and not a simple activation of current by 
low pH, since ASIC channels, and ASIC1a in particular, are transiently active channels and desensitize 
after a few seconds of exposure to low pH[68]. 
Potassium channels 
The potassium channel superfamily consists of over 70 subtypes and they are involved in several dif-
ferent levels of OA progression[31].  The classical two, four and six trans-membrane domain potas-
sium channels (Kir1-7: Inward rectifiers, K2P: Tandem pore and KV/KCa: Voltage-gated and calcium-
activated potassium channels, respectively) are highly selective for potassium ions. Generally, potas-
sium channels have a role in stabilizing the membrane potential or in action potential repolarization.  
As such, potassium channel modulation is a common physiological mechanism of changing the excit-
ability of a neurone.  In other cell types, such as chondrocytes and glial cells, potassium channels 
serve important roles in cell volume regulation, apoptosis and maintenance of potassium homeosta-
sis[31].  There are a number of existing drugs used which currently target potassium channels in dis-
eases such as diabetes, hypertension, epilepsy and angina [69], but none which are yet used clini-
cally as analgesics. KiR3.x (GIRK), which couple to opioid receptors, could be one such target. Side 
effects of current centrally acting opioid drugs (somnia, euphoria, addiction etc.) limit their useful-
ness, but recently it has become clear that opioid receptors also mediate effective analgesia when 
applied peripherally[70].  Such µ-opioid agonists, could prove extremely useful analgesics for chronic 
pain conditions such as OA.  So too could activation of the peripheral downstream apparatus of the 
µ-opioid receptor such as GIRK.  In rats and humans, the peripheral analgesia of the inflammatory 
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neuropathic pain model is almost entirely dependent on GIRK[71]. This raises GIRK itself as a poten-
tial OA analgesia target.  Interestingly, the work of Nockemann et al[71] found GIRK to be absent 
from mouse peripheral neurones in striking contrast to their human and rat counterparts.  Another 
related and highly selective potassium channel implicated in inflammatory OA pain is the M-current 
potassium channel, or KV7.x; this channel is activated by bradykinin in chronic inflammatory pain[72-
73].  Bradykinin is strongly implicated in all kinds of inflammatory pain; some of its inflammatory ac-
tions are mediated by opioid receptors[74] and it can act synergistically with prostanoids further 
contributing to joint degeneration in OA[75].  Antagonists of the bradykinin B2 receptor have there-
fore been proposed to be potentially useful treatment agents for OA[76].  Bradykinin (along with the 
neurokinin-1 receptor) is also found to be over expressed in neurones in induced arthritis pain mod-
els[77-78] and a selective bradykinin receptor-2 antagonist (fasitibant) prevents the associated hy-
peralgesia[78].  BK directly sensitizes joint afferents[79] and BK antagonists have been used in the 
MIA model[80].  Future treatment options could also include targeting bradykinin’s effector ion 
channels including GIRK, calcium-activated chloride channels[72-73] and TRPV1 (see below). 
There are a number of cation channels which express weaker selectivity for potassium, such 
as the hyperpolarization-activated cyclic nucleotide gated (HCN) channels[81].  HCN channels are a 
relatively small subfamily of ion channels (HCN1 to HCN4) that are closely related to the other cyclic 
nucleotide gated (CNG) channels.  Often classified as non-selective, they actually have a K+ to Na+ 
selectivity ratio of approximately 5:1 and are thus weakly selective potassium channels[81].  HCN 
channels can be activated by cGMP (and cAMP) although the mechanism involves shifts in their 
voltage activation sensitivity.  HCN channels are expressed in neurones innervating the rat temporo-
mandibular joint and contribute to inflammation-induced mechano-hypersensitivity where ZD7288 
(a selective HCN blocker) exhibits profound anti-mechanical hypersensitivity activity[82]. The 
expression of these channels in both cardiac and sensory tissues may limit the translation of these 
drugs to clinical trials unless they can be shown to discriminate between the two tissues with high 
selectivity. 
Transient Receptor Potential (TRP) Channels and Calcium Channels 
TRP ion channels are emerging as widely expressed molecular sensors in the musculoskeletal system
[48, 83].  Most of these channels have significant permeability for calcium ions, and some are highly 
selective for calcium. TRP channels are important, not just to the function of chondrocytes[25, 45], 
but also in the progression of OA pain.  For example, in addition to activating potassium channels, 
bradykinin also contributes to joint pain by activating a range of TRP channels such as TRPV1[84-85], 
TRPV4 and TRPA1[86-87].  TRPV1 and TRPV4 are also activated by protease activated receptor (PAR-
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2), another inflammatory receptor with particular relevance to OA; PAR-2 couples to TRPV1/4, 
stimulates pain and exacerbates OA progression[47, 88].  Furthermore TRPV1 is up-regulated in joint 
primary afferent neurons the MIA model of OA[44] and TRPV1 KO decreases pain responses to both 
chemical and thermal stimuli of mouse paw[89].  These channels have also been identified in mouse 
ankle and knee [90].  Further interest has surrounded potential inhibition of TRPV1 in OA chronic 
pain since Chapman and colleagues show an association with the Ile585Val TRPV1 variant is involved 
in risk of painful knee OA[91].  Application of the TRPV1 inhibitor A-889425 did decrease afferent 
nerve activity in CFA-hyperalgesia rats[92] and A-995662 (another TRPV1 antagonist) successfully 
reduced MIA induced changes in grip force, but in contrast the alternative TRPV1 inhibitor AMG9810 
did not appear to reduce OA pain[93].  The potential benefits of selective TRPV1 drugs are 
enormous, but have yet to be realised due to potential side effects.  It should be said however, that 
the total selectivity of any novel inhibitors such as A889425 and AMG-9810 takes many years to es-
tablish.  In this particular case, the two compounds are chemically rather different; being a trifluoro-
methylsulfonyl-phenyl and a 1,4-benzodioxine respectively. Encouragingly, antisense knockdown of 
the closely related TRPA1 channel also reduces pain in a model of neuropathic pain[94], however, 
systemic TRPA1 inhibition (A-967079 or HC030031) is ineffective in reversal of CFA-hyperalgesia or 
MIA-induced joint pain [93, 95].  
Cannabinoids (CB) have been extensively studied as potential modulators of chronic pain.  
Reports of their efficacy for OA pain have been conflicting, with promising data emerging from ani-
mal models[96-97], but less promising data resulting from clinical trials[98].  Some of this divergence 
may result from currently unknown differences in ion channels between species, as discussed for 
GIRK above[71], but other issues may involve the rather complex actions of cannabinoids on CB re-
ceptors and TRP channels.  For example, CB2 receptors are co-localized with TRPV1 receptors in DRG 
and the selective agonist GW405833 appears to decrease afferent nerve firing in control knees, but 
increase nociceptive firing in MIA-treated OA rat knees[99].  The latter effect appears to involve 
TRPV1, possibly through a CB2-TRPV1 positive coupling.  The TRP family contains dozens of sub-
members however, and it is likely that other members also play a role in OA pain, for example, 
TRPM3 is expressed in DRGs and trigeminal ganglia sensory neurones, is activated by heat and it has 
been shown that TRPM3-/- mice have impaired sensation of noxious heat and thermal hyperalgesia
[100]. 
VGCC are important for Ca2+ entry in most neurotransmission and are one of the targets of 
CNS endorphins and enkephalins (and their exogenous counterparts, the opioids, e.g., morphine). 
Unsurprisingly, therefore, VGCC are also involved with chronic and neuropathic pain[101].  In 
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particular, the α2d-1 subunit of VGCC is increased in MIA-induced OA and thus contributes to the 
generation of pain[102].  A number of VGCC blockers are available and one in particular, 
gabapentin, is of potential benefit for treatment of OA pain[103]. Interestingly, gabapentin appears 
to be only in use by a very small cohort of OA patients[104].  Store-operated calcium channel 
inhibitors have also been recently implicated as potential analgesics for chronic inflammatory pain
[105].   
Purinergic channels 
The purinergic membrane receptor super-family is classed into P1 and P2 receptor families of which 
the P2 family are of particular relevance to OA pain.  These are activated by extracellular nucleo-
tides (ATP or ADP).  P2X are ligand-gated ion channel receptors (P2X1-7), whereas P2Y are G-protein 
coupled receptors.  Several members of this family have been identified in cartilage including; P2X2, 
P2X3, P2X4 and P2X7[106-107]. It has been shown that P2 receptor signalling is altered in OA[108] 
with elevated levels of ATP inducing desensitisation of purinergic membrane receptors.  In terms of 
the OA pain pathway, P2X receptors have also been identified in peripheral glial cells and play a role 
in neuropathic pain[109]. Glial cells (peripheral and spinal) are non-excitable cells in the nervous 
system and express a large range of ion channels and receptors which are likely to contribute to the 
onset of neuropathic-type pain including a component of OA[109-110].  Glial cells produce a variety 
of proinflammatory mediators, including IL-1β, TNF-α, and NO. Following peripheral nerve damage, 
P2X4 receptor upregulation in spinal microglia cells and P2X7 upregulation in macrophages has 
been reported[3].  Human studies have also shown that both the P2X7 and microglial cell expression 
has increased following chronic pain[3]. This channel plays a part in the initiation of neuroinflamma-
tion[111] and recent studies have developed a novel P2X7 antagonist, JNJ-47965567[112], which 
could be of potential benefit as an OA pain analgesic.  Whilst it exerted only modest analgesia in a 
rat spinal lesion model of neuropathic pain[112], it is highly selective and readily penetrates the CNS 
and so could potentially act at any point along the ascending OA pain pathway.   
Conclusions 
In many ways OA typifies chronic pain with remodelling of joints, plasticity of innervation and affer-
ent nociceptive pathways.  However, unlike idiopathic chronic pain, there are also established no-
ciceptive mechanisms involving ion channels in joints and primary afferent neurones.  There is little 
specific evidence to class OA as a channelopathy as such, but clear evidence suggests that both pain 
generation and cartilage degeneration involve ion channels.  Numerous studies discussed in this 
review also highlight the coupling between joint degeneration, inflammation and nociception in ac-
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counter-intuitive direction.  Targeting these ion channels is therefore a highly important objective 
for those developing treatments for OA pain.   
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